During the corresponding time, Natera Inc recorded a revenue increase by 37.71 % year on year, sequentially revenue grew by 8.05 %. While revenue at the Natera Inc 's corporate clients
Natera Inc's Comment on Sales, Marketing and Customers
The company offers diagnostic tests including aneuploidies and microdeletions in non-invasive prenatal testing (NIPT) and expanded carrier screening tests. Customers utilize Current Procedural Terminology (CPT) codes to bill and obtain reimbursement for these tests. The American Medical Association (AMA) establishes CPT codes, while payment levels and coverage rules are determined by the Centers for Medicare & Medicaid Services (CMS), state Medicaid programs, and commercial health plans. CMS has set pricing benchmarks of $802 for aneuploidy and microdeletions testing and approximately $2,450 for expanded carrier screening testing. The company's Signatera test has received Medicare Part B coverage and Advanced Diagnostic Laboratory Test (ADLT) status. The company submits reimbursement claims using CPT codes but faces risks related to code rejection, withdrawal, or unfavorable reimbursement rates, particularly for microdeletions testing where reimbursement rates have been low.
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity In a significant advancement in the field of precision medicine, Natera, Inc. (NASDAQ: NTRA) has announced promising results from its recent phase of the PROCEED-CRC trial, which is assessing a novel blood-based screening test for colorectal cancer (CRC) and advanced adenomas (AA). Natera, a global leader in cell-free DNA and precision medicine, is pioneering this approach to enhance early detection and intervention strategies for high-risk conditions.The PROCEED-CRC clinical trial, designated under the identifier NCT06620627, is a U.S.-based, prospective study aimed at valida...
In a groundbreaking announcement from Austin, Texas, Natera, Inc. (NASDAQ: NTRA), a leading figure in the realm of cell-free DNA and genetic testing, has unveiled remarkable findings from its pioneering DEFINE-HT study during the International Society for Heart and Lung Transplantation s 45th Annual Meeting in Boston, MA. The study, hailed as the first prospective multicenter trial focusing on heart transplant recipients, establishes the Prospera Heart test not merely as a diagnostic tool, but as a reliable predictor of clinical outcomes in graft dysfunction.The DEFINE-HT study sets a new benchmark in heart transplantation by demonstrating that elevated levels of donor-derived cell-free DNA are indicative of...
Natera s Groundbreaking Study on Heart Transplant Recipients and Improved Financial Resilience In a groundbreaking move for the field of transplantation medicine, Natera, Inc. (NASDAQ: NTRA) has been selected to present late-breaking findings from its DEFINE-HT study at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting, set to be held in Austin, Texas, on April 29, 2025. This study marks a significant milestone as the first prospective, multicenter research initiative aimed explicitly at heart transplant recipients, aimed at understanding the implications of elevated donor-derived cell-free DNA (dd-cfDNA) levels.As a global leader in cell-free DNA and genetic t...
Natera to Present Groundbreaking Data at the 2025 ASCO GI Symposium in San Francisco AUSTIN, Texas Natera, Inc. (NASDAQ: NTRA), a pioneer in the field of cell-free DNA and genetic testing, is poised to make significant contributions to cancer research at the upcoming American Society of Clinical Oncology s Gastrointestinal Cancers Symposium (ASCO GI) scheduled for January 23-25, 2025, in San Francisco, California. The event will showcase a series of compelling abstracts that are set to redefine the understanding and management of gastrointestinal cancers. Overview of ASCO GI SymposiumThe ASCO GI Symposium is a premier gathering for professionals in the field of gastrointestinal oncology, serving as a platf...
A Breath of Fresh Air: Medicare Coverage for Natera s Prospera Lung Test Targets Single Lung Transplants In a significant stride for post-transplant care, Natera, Inc. a pioneer in cell-free DNA and genetic testing announced that its Prospera Lung test has secured coverage from the Centers for Medicare and Medicaid Services (CMS) Molecular Diagnostics Services (MolDX) Program. The pivotal development spells good news for single lung transplant (SLT) recipients, a group that comprises approximately 20% of all lung transplant patients in the United States.These patients are often at an increased risk of complications and require vigilant post-operative monitoring. The Prospera Lung test offers a sophisticated,...
Natera, Inc. (NASDAQ: NTRA), a front-runner in the field of cell-free DNA and genetic testing, has recently garnered significant recognition. The company’s co-founder and executive chairman, Matthew Rabinowitz, PhD, was honored as the RandD Leader of the Year for 2024 by RandD World, a testament to Natera s substantial contributions to innovative technologies in the genomic testing space. The RandD 100 Awards, which have been celebrating groundbreaking inventions since 1963, highlight pivotal advancements, and Rabinowitz s recognition reflects Natera s status as an industry leader.Natera has established a reputation for pushing the boundaries of genetic testing and liquid biopsy technologies. The award rec...
In the realm of oncology, the integration of advanced genomic technologies holds transformative potential for enhancing patient outcomes, particularly in aggressive cancers such as Merkel cell carcinoma (MCC) and breast cancer. Natera, Inc. (NASDAQ: NTRA), a trailblazer in cell-free DNA (cfDNA) testing, has recently underscored its commitment to precision medicine through a series of groundbreaking studies and product innovations. Central to this evolution is Natera s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, which has garnered attention in the Journal of Clinical Oncology and JCO Precision Oncology for its robust clinical applications.Merkel cell carcinoma, characteri...
Natera Revolutionizes Transplant Patient Care with Advanced Prospera Heart Test Enhancement and Launches Innovative Solutions for Breast Cancer and RhD TestingAustin, Texas - Natera, Inc., a leading global provider of cell-free DNA (cfDNA) and genetic testing, has unveiled groundbreaking advancements in medical technology that are set to transform patient care across multiple fields. The company s latest innovation, the Prospera Heart with Donor Quantity Score (DQS), significantly enhances the detection of rejection in heart transplant patients. This development aims to revolutionize the monitoring and treatment of transplant recipients, ultimately leading to improved outcomes.Traditionally, rejection risk i...
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Early-Stage Breast Cancer PatientsAustin, Texas - Natera, Inc. (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing, has released a new publication in JCO Precision Oncology providing compelling evidence of the effectiveness of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in detecting recurrence at an early stage in patients with early-stage breast cancer. The full study can be accessed here, giving readers valuable insights into the study s findings.The study analyzed a total of 1,136 plasma samples that were prospectively collected and stored from 156 patients with...
Natera, Inc., a prominent player in the cell-free DNA and genetic testing industry, has recently introduced a new cell-free DNA-based fetal RhD test. This breakthrough comes at a critical time for healthcare providers and patients as the nationwide shortage of Rho(D) immune globulin therapy (RhIg) poses challenges in patient care. The test, which can be conducted as early as nine weeks gestation, offers valuable insights into fetal RhD status using the blood of pregnant patients. Additionally, this article will discuss Natera s recent victories in patent infringement lawsuits.In response to the pressing need to support ob/gyn physicians and patients during the current RhIg shortage, Natera has developed a no...
Natera Inc’s Comment on Sales, Marketing and Customers
The company offers diagnostic tests including aneuploidies and microdeletions in non-invasive prenatal testing (NIPT) and expanded carrier screening tests. Customers utilize Current Procedural Terminology (CPT) codes to bill and obtain reimbursement for these tests. The American Medical Association (AMA) establishes CPT codes, while payment levels and coverage rules are determined by the Centers for Medicare & Medicaid Services (CMS), state Medicaid programs, and commercial health plans. CMS has set pricing benchmarks of $802 for aneuploidy and microdeletions testing and approximately $2,450 for expanded carrier screening testing. The company's Signatera test has received Medicare Part B coverage and Advanced Diagnostic Laboratory Test (ADLT) status. The company submits reimbursement claims using CPT codes but faces risks related to code rejection, withdrawal, or unfavorable reimbursement rates, particularly for microdeletions testing where reimbursement rates have been low.
Sources:
Natera Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Natera Inc’s corporate clients.
For your research, we’ve provided 9 tables on Natera Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
191.54 %